Get detailed information on Abemaciclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

Tango Therapeutics (TNGX) announced an update on its PRMT5 program. Based on data from the dose escalation and early dose expansion cohorts of ...

Tango Therapeutics (TNGX) stock plunged 28% Wednesday after the company announced updates on several drug candidates and released its Q3 earnings report. Read more here.

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

There were also strong gains for psoriasis therapy Taltz (ixekizumab), diabetes and heart failure therapy Jardiance (empagliflozin), and breast cancer therapy Verzenio (abemaciclib). Eisai has ...